Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Fall;24(3):e50-2.
doi: 10.1155/2013/535616.

Assessment of linezolid efficacy, safety and tolerability in the treatment of tuberculosis: A retrospective case review

Alena Tse-Chang  1 , Dennis Kunimoto  2 , Evelina Der  3 , Rabia Ahmed  2
Affiliations

Assessment of linezolid efficacy, safety and tolerability in the treatment of tuberculosis: A retrospective case review

Alena Tse-Chang et al. Can J Infect Dis Med Microbiol. 2013 Fall.

Abstract
in English, French

Linezolid is a potentially effective drug for the treatment of patients with drug-resistant tuberculosis. Among 13 patients treated for tuberculosis with linezolid in the present study, nine had treatment success and four remain on treatment. Adverse effects occurred in 11 (85%) patients, of whom three discontinued treatment because of adverse effects. The present study adds to the growing evidence supporting the efficacy of linezolid for tuberculosis, although treatment remains complicated by adverse effects.

Le linézolide est un médicament qui peut être efficace dans le traitement de patients atteints d’une tuberculose résistant aux médicaments. Dans la présente étude, chez 13 patients traités au linézolide contre la tuberculose, neuf ont vu leur traitement réussir et quatre sont toujours en traitement. Des effets indésirables se sont manifestés chez 11 (85 %) patients, dont trois ont arrêté le traitement pour cette raison. La présente étude s’ajoute aux données croissantes étayant l’efficacité du linézolide pour soigner la tuberculose, même si le traitement demeure compliqué par des effets indésirables.

Keywords: Drug-resistant TB; Linezolid; Toxicity; Treatment outcomes.

PubMed Disclaimer

References

    1. Park IN, Hong SB, Oh YM, et al. Efficacy and tolerability of daily half dose linezolid in patients with intractable multidrug resistant TB. J Antimicrob Chemother. 2006;58:701–4. - PubMed
    1. von der Lippe B, Sandven P, Brubakk O. Efficacy and safety of linezolid in multidrug resistant TB (MDR-TB) – a report of ten cases. J Infect. 2006;52:92–6. - PubMed
    1. Condos R, Hadgiangelis N, Leibert E, et al. Case series report of a linezolid-containing regimen for extensively drug-resistant TB. Chest. 2008;134:187–92. - PubMed
    1. Yew WW, Chau CH, Wen KH. Linezolid in the treatment of ‘difficult’ multidrug-resistant tuberculosis. Int J Tuberc Lung Dis. 2008;12:345–6. - PubMed
    1. Fortun J, Martin-Davila P, Navas E, et al. Linezolid for the treatment of multidrug-resistant tuberculosis. J Antimicrob Chemother. 2005;56:180–5. - PubMed

LinkOut - more resources